

12 May 2015

ASX ANNOUNCEMENT

More Pentrox Licensing Agreements Expected

To facilitate distributing Pentrox internationally, Medical Developments International Limited (ASX: MVP) established a restricted confidential electronic data room in FY14 for prospective license partners. The data room has attracted more than 30 companies and to date MVP has concluded Licensing & Distribution agreements for Pentrox in England, Ireland and the Republic of Ireland, Scotland, Wales, South Africa, Mexico, Singapore, Saudi Arabia, Taiwan, Hungary, UAE and Hong Kong. Together these agreements have significant minimum sales quantities which will underwrite MVP's future sales growth.

In anticipation of getting Pentrox approved in the European Union, a Licensing & Distribution agreement was signed with Galen Limited in September 2014 for the United Kingdom and Ireland. MVP is in advanced negotiations with pharma companies to license and distribute Pentrox in Germany, Spain, Italy, and with others interested in the whole of Western Europe.

MVP CEO, Mr. John Sharman said, "Now that we have the 'green light' from the MHRA for the UK, France, Belgium and Ireland we expect to conclude Licensing & Distribution agreements for other EU countries in the coming months. Such deals are expected to be in a similar form to that signed with Galen and therefore are expected to involve significant upfront and other milestone payments. Accordingly we expect sales into the major markets of the EU over the next 12 months, starting with sales into the UK and Ireland where preparations are well advanced for a July launch and followed shortly after in France and Belgium. Subject to mutual recognition regulations, the company is expecting sales into Germany, Italy and Spain in FY16."

"Several companies are in negotiations for the rights to countries outside the EU, including Turkey, Israel, Canada, Russia, Japan, Malaysia, South Korea, Bahrain and Latin America. MVP hopes to consummate many of these agreements in CY15 at the same time as regulatory approvals are progressing.

Enquiries:

David Williams
Chairman
+61 (0) 414 383 593

John Sharman
Chief Executive Officer
+61 (3) 9547 1888



About Pentrox

Penthrox is a fast onset, non-opioid analgesic indicated for pain relief by self-administration in patients with trauma and those requiring analgesia for surgical procedures. Penthrox has been used safely and effectively for more than 30 years in Australia with excess of 5.0 million units sold. There is growing interest in Penthrox being used in patients undergoing investigatory procedures, as well as operational procedures such as colonoscopy.

About Medical Developments International Ltd

MVP is an Australian company delivering emergency medical solutions dedicated to improving patient outcomes. MVP is a leader in emergency pain relief and respiratory products. The Company manufactures Penthrox[®], a fast acting trauma & emergency pain relief product. It is used in Australian Hospitals including Emergency Departments, Australian Ambulance Services, the Australian Defence Forces, Sports Medicine and for analgesia during short surgical procedures such as Dental and Cosmetic surgery as well as in other medical applications. MVP is expanding internationally and manufactures a range of world-leading Asthma respiratory devices.